{
    "paper_id": "b69e64ed79854a83515565c1419a1274d798af6f",
    "metadata": {
        "title": "Journal Pre-proof Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals Detection of SARS-CoV-2-specific humoral and cellular immunity in 2",
        "authors": [
            {
                "first": "Ling",
                "middle": [],
                "last": "Ni",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tsinghua University",
                    "location": {
                        "postCode": "10 100084",
                        "settlement": "Beijing",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Fang",
                "middle": [],
                "last": "Ye",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Meng-Li",
                "middle": [],
                "last": "Cheng",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Yu",
                "middle": [],
                "last": "Feng",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tsinghua University",
                    "location": {
                        "postCode": "10 100084",
                        "settlement": "Beijing",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Yong-Qiang",
                "middle": [],
                "last": "Deng",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Hui",
                "middle": [],
                "last": "Zhao",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Peng",
                "middle": [],
                "last": "Wei",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jiwan",
                "middle": [],
                "last": "Ge",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tsinghua University",
                    "location": {
                        "postCode": "10 100084",
                        "settlement": "Beijing",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Mengting",
                "middle": [],
                "last": "Gou",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tsinghua University",
                    "location": {
                        "postCode": "10 100084",
                        "settlement": "Beijing",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Xiaoli",
                "middle": [],
                "last": "Li",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tsinghua University",
                    "location": {
                        "postCode": "10 100084",
                        "settlement": "Beijing",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Lin",
                "middle": [],
                "last": "Sun",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tsinghua University",
                    "location": {
                        "postCode": "10 100084",
                        "settlement": "Beijing",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Tianshu",
                "middle": [],
                "last": "Cao",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Pengzhi",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tsinghua University",
                    "location": {
                        "postCode": "10 100084",
                        "settlement": "Beijing",
                        "country": "China"
                    }
                },
                "email": ""
            },
            {
                "first": "Chao",
                "middle": [],
                "last": "Zhou",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Rongrong",
                "middle": [],
                "last": "Zhang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Peng",
                "middle": [],
                "last": "Liang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Han",
                "middle": [],
                "last": "Guo",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Xinquan",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Cheng-Feng",
                "middle": [],
                "last": "Qin",
                "suffix": "",
                "affiliation": {},
                "email": "cheng-fengqin@bmi.ac.cn."
            },
            {
                "first": "Fang",
                "middle": [],
                "last": "Chen",
                "suffix": "",
                "affiliation": {},
                "email": "fangchen@163.com"
            },
            {
                "first": "Chen",
                "middle": [],
                "last": "Dong",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "Tsinghua University",
                    "location": {
                        "postCode": "10 100084",
                        "settlement": "Beijing",
                        "country": "China"
                    }
                },
                "email": "chendong@tsinghua.edu.cn"
            },
            {
                "first": "L",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "F",
                "middle": [],
                "last": "Cheng",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "M.-L",
                "middle": [],
                "last": "Feng",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Y",
                "middle": [],
                "last": "Deng",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Y.-Q",
                "middle": [],
                "last": "Zhao",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "H",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Wei",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "P",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "J",
                "middle": [],
                "last": "Gou",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "M",
                "middle": [],
                "last": "Li",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "X",
                "middle": [],
                "last": "Sun",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "L",
                "middle": [],
                "last": "Cao",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "T",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "P",
                "middle": [],
                "last": "Zhou",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "C",
                "middle": [],
                "last": "Zhang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "R",
                "middle": [],
                "last": "Liang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "P",
                "middle": [],
                "last": "Guo",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "H",
                "middle": [],
                "last": "Wang",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "X",
                "middle": [],
                "last": "Qin",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "C.-F",
                "middle": [],
                "last": "Chen",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "F",
                "middle": [],
                "last": "Dong",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "C",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "",
                "middle": [],
                "last": "Chao",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Zhou",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "*These authors contributed equally to this work.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "1 2 #To whom correspondence should be addressed: Chen Dong, chendong@tsinghua.edu.cn; 3 or Fang Chen, anzhenchenfang@163.com; Cheng-Feng Qin, qincf@bmi.ac.cn. 14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49 1 Introduction 1 At the end of 2019, patients with Coronavirus Disease 2019 were identified 2 in Wuhan, China (Wang et al., 2020) , infected by a novel coronavirus, now named as severe 3 acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization 4 (WHO) first declared this outbreak a public health emergency of international concern 5 (Phelan et al., 2020) and subsequently a world-wide pandemic (Di Pierro et al., 2020) .",
            "cite_spans": [
                {
                    "start": 406,
                    "end": 431,
                    "text": "China (Wang et al., 2020)",
                    "ref_id": null
                },
                {
                    "start": 725,
                    "end": 749,
                    "text": "(Di Pierro et al., 2020)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 159,
                    "end": 301,
                    "text": "14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49",
                    "ref_id": "TABREF0"
                }
            ],
            "section": ""
        },
        {
            "text": "The genome sequence of SARS-CoV-2 bears 96% (Zhou et al., 2020) and 79.5% 7 identity to that of a bat coronavirus and SARS-CoV, respectively (Zhu et al., 2020) . Like 8 SARS-CoV and MERS-CoV, SARS-CoV-2 belongs to the beta genus Coronavirus in the 9 Corornaviridae family (Lu et al., 2020) . Clinically, several papers showed that most COVID-10 19 patients developed lymphopenia as well as pneumonia with higher plasma levels of pro-11 inflammatory cytokines in severe cases (Chan et al., 2020; Huang et al., 2020; Wu et al., 12 2020), suggesting that the host immune system is involved in the pathogenesis (Mahallawi 13 et al., 2018; Nicholls et al., 2003) . Patients infected by SARS-CoV or MERS-CoV were 14 previously reported to have antibody responses (Ko et al., 2017; Shi et al., 2004; Wang et al., (Thevarajan et al., 2020) . One COVID-19 patient in 1 Finland was shown to possess a low level of neutralizing antibody titer (Haveri et al., 2020) .",
            "cite_spans": [
                {
                    "start": 44,
                    "end": 63,
                    "text": "(Zhou et al., 2020)",
                    "ref_id": null
                },
                {
                    "start": 141,
                    "end": 159,
                    "text": "(Zhu et al., 2020)",
                    "ref_id": null
                },
                {
                    "start": 272,
                    "end": 289,
                    "text": "(Lu et al., 2020)",
                    "ref_id": null
                },
                {
                    "start": 475,
                    "end": 494,
                    "text": "(Chan et al., 2020;",
                    "ref_id": null
                },
                {
                    "start": 495,
                    "end": 514,
                    "text": "Huang et al., 2020;",
                    "ref_id": null
                },
                {
                    "start": 515,
                    "end": 525,
                    "text": "Wu et al.,",
                    "ref_id": null
                },
                {
                    "start": 607,
                    "end": 634,
                    "text": "(Mahallawi 13 et al., 2018;",
                    "ref_id": null
                },
                {
                    "start": 635,
                    "end": 657,
                    "text": "Nicholls et al., 2003)",
                    "ref_id": null
                },
                {
                    "start": 757,
                    "end": 774,
                    "text": "(Ko et al., 2017;",
                    "ref_id": null
                },
                {
                    "start": 775,
                    "end": 792,
                    "text": "Shi et al., 2004;",
                    "ref_id": null
                },
                {
                    "start": 793,
                    "end": 805,
                    "text": "Wang et al.,",
                    "ref_id": null
                },
                {
                    "start": 806,
                    "end": 831,
                    "text": "(Thevarajan et al., 2020)",
                    "ref_id": null
                },
                {
                    "start": 932,
                    "end": 953,
                    "text": "(Haveri et al., 2020)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "6"
        },
        {
            "text": "However, virus-specific T lymphocytes and their relationships with neutralizing antibody 3 titers in COVID-19 patients remains uncharacterized.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "2"
        },
        {
            "text": "In this study, we collected blood from COVID-19 patients who have recently become 5 virus-free and therefore were discharged, and analyzed their SARS-CoV-2-specific antibody 6 and T cell responses. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "4"
        },
        {
            "text": "whereas the remaining 6 were 2 weeks post discharge (follow-up patients, patients #9-14).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "14"
        },
        {
            "text": "Only three travelled to Wuhan city within the past 3 months. In line with the previous reports 16 (Wang et al., 2016) , 2 patients (#5, 10) showed lymphopenia (normal range is 1.1-3.2X10e9 17 cells per L). Sera from three healthy donors (Wang et al., 2016) were obtained before the 18 SARS-CoV-2 outbreak (healthy donor #1-3). 3 additional healthy donors (#4-6) who had 19 been in close contacts with the patients were recruited in this study. Human AB serum 20 collected from healthy male AB donors in the US (GemCell, CA) was used as a negative 21 control.",
            "cite_spans": [
                {
                    "start": 98,
                    "end": 117,
                    "text": "(Wang et al., 2016)",
                    "ref_id": null
                },
                {
                    "start": 237,
                    "end": 256,
                    "text": "(Wang et al., 2016)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "15"
        },
        {
            "text": "In order to detect anti-viral immune responses, we first constructed recombinant pET28-23 N-6XHis by linking 6 copies of His tag to the C-terminus of NP in the pET28-N vector 24 (Biomed, Cat. number: BM2640). Escherichia coli transformed with pET28-N-6xHis was 25 lysed and tested by Coomassie blue staining to confirm NP expression at 45.51 kDa. NP 26 was further purified by Ni-NTA affinity chromatography and gel filtration. The purity of NP 27 was approximately 90% ( Figure S1A ). The presence of NP was subsequently confirmed by 28 anti-Flag antibody ( Figure S1B ). The receptor-binding domain (RBD) of S protein (S-RBD) 1 and main protease (Lan et al., 2020) were produced by a Baculovirus insect expression 2 system and purified to a purity of 90% ( Figure S1A ).",
            "cite_spans": [
                {
                    "start": 648,
                    "end": 666,
                    "text": "(Lan et al., 2020)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 472,
                    "end": 482,
                    "text": "Figure S1A",
                    "ref_id": null
                },
                {
                    "start": 559,
                    "end": 569,
                    "text": "Figure S1B",
                    "ref_id": null
                },
                {
                    "start": 759,
                    "end": 769,
                    "text": "Figure S1A",
                    "ref_id": null
                }
            ],
            "section": "22"
        },
        {
            "text": "Using sera from patients and healthy donors, IgG and IgM against SARS-CoV-2 NP, 4 main protease and S-RBD antigens were analyzed. There was no significant antibody 5 response to main protease in sera from several patients (data not shown), suggesting that it 6 may not serve as an antigen for humoral immunity. We thus focused on NP and S-RBD. The 7 individual serum samples were then performed by serial dilutions to get optimal dilutions 8 ( Figure 1A ). Dilution of 1:50 was used for IgM and 1:450 for IgG. NP-and S-RBD-specific 9 IgM and IgG antibodies were both detected in the sera of newly discharged patients, 10 compared with healthy donor groups. Anti-SARS-CoV-2 IgG antibodies were also more 11 obviously observed than IgM in the follow-up patients (#9-14), when compared with healthy 12 donors ( Figure 1B ). In addition, values from the serum dilution curves were calculated to 13 determine the area under the curve (AUC) values. Compared to control sera, COVID-19 14 patient sera showed significantly higher AUC for NP-and S-RBD-specific IgG antibodies 15 ( Figure 1C ). Taken together, these findings indicate that COVID-19 patients mounted IgG 16 and IgM responses to SARS-CoV-2 proteins, especially NP and S-RBD, and also suggest 17 that infected patients could maintain their IgG amounts, at least for two weeks after 18 discharge.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 444,
                    "end": 453,
                    "text": "Figure 1A",
                    "ref_id": null
                },
                {
                    "start": 808,
                    "end": 817,
                    "text": "Figure 1B",
                    "ref_id": null
                },
                {
                    "start": 1072,
                    "end": 1081,
                    "text": "Figure 1C",
                    "ref_id": null
                }
            ],
            "section": "3"
        },
        {
            "text": "In addition, IgG isotypes was further tested in 14 patients and 6 controls. As shown in 20 Figure 1D , anti-NP and S-RBD IgG was mainly IgG1 isotype, and the newly discharged and 21 follow-up patients showed similarly amounts of anti-NP IgG1. Of interest, one patient (Pt#5)",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 91,
                    "end": 100,
                    "text": "Figure 1D",
                    "ref_id": null
                }
            ],
            "section": "19"
        },
        {
            "text": "showed higher amounts of anti-NP IgG3, whereas anti-S-RBD IgG3 was detected in two 23 patients (Pt#4-5). However, we did not detect IgG2 to either NP or S-RBD proteins (data not 24 shown).",
            "cite_spans": [],
            "ref_spans": [],
            "section": "22"
        },
        {
            "text": "Since the RBD of the S protein has been shown to bind to human angiotensin 1 converting enzyme 2 (ACE2) (Zhou et al., 2020) , the existence of antibodies against it may 2 suggest neutralization of SARS-CoV-2 infection. To assess this, we performed pseudovirus 3 particle-based neutralization assay, since there was a significantly positive correlation in the 4 neutralizing antibody titers between pseudovirus and SARS-CoV-2 ( Figure 2A ). As shown in 5 Figure 2B and 2C, patients #1, 2, 4, 5 and 8, all within the newly discharged group, had high 6 neutralizing antibody titers. These results demonstrate that most recently discharged 7 patients had strong humoral immunity to SARS-CoV-2. Among the follow-up patients, all had 8 neutralizing antibody titers with the exception of patient #9 being negative. As expected, 9 there was a significant correlation between neutralizing antibody titers and AUC of anti-S- ",
            "cite_spans": [
                {
                    "start": 104,
                    "end": 123,
                    "text": "(Zhou et al., 2020)",
                    "ref_id": null
                }
            ],
            "ref_spans": [
                {
                    "start": 427,
                    "end": 436,
                    "text": "Figure 2A",
                    "ref_id": null
                },
                {
                    "start": 454,
                    "end": 463,
                    "text": "Figure 2B",
                    "ref_id": null
                }
            ],
            "section": "27"
        },
        {
            "text": "To explore cellular immune responses to SARS-CoV-2, we isolated peripheral blood 16 monocytic cells (PBMCs) from the whole blood and phenotypically analyzed them by flow 17 cytometry ( Figure 3A ). We found that compared to newly discharged patients, there was a 18 trend towards an increased frequency of NK cells in the follow-up patients ( Figure 3B ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 185,
                    "end": 194,
                    "text": "Figure 3A",
                    "ref_id": null
                },
                {
                    "start": 343,
                    "end": 352,
                    "text": "Figure 3B",
                    "ref_id": null
                }
            ],
            "section": "15"
        },
        {
            "text": "However, there was no significant difference in terms of the percentages of T cells among 20 those two groups and the healthy donors.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "19"
        },
        {
            "text": "To assess virus-specific cellular immunity, we then treated PBMCs with recombinant NP, 22 main protease and S-RBD, followed by IFN-\u03b3 ELISpot analysis. The results were considered 23 positive if there were at least 2-fold increase in the numbers of IFN-\u03b3-secreting T cells in the 24 subject than in the healthy donors. As shown in Figure 3C , compared with healthy donors, 25 the numbers of IFN-\u03b3-secreting NP-specific T cells in patients #1, 2, 4, 5 and 8 were much 26 higher than other patients, suggesting that they had developed SARS-CoV-2-specific T cell responses. Of note, patients #1, 2, 4, 5 and 8 developed both strong humoral and cellular 1 immune responses. Main protease-specific T cells were detected in patient #1, 2 and 5, 2 while patients # 1, 2, 4, 5, 6, 7 and 8 showed S-RBD-specific T cells. Although the numbers 3 of IFN-\u03b3-secreting S-RBD specific T cells were much lower than those of NP-specific T cells, 4 they could be detected in more patients than those for other viral proteins. In the follow-up 5 patients, only patient #10 who showed lymphopenia before treatment still had a high number 6 of IFN-\u03b3-secreting T cells in response to NP, main protease and S-RBD ( Figure 3C ), which 7 suggests that anti-viral T cells may not be maintained at high numbers in the PBMCs in the 8 recovered patients. More interestingly, when combining all 14 patients in our analysis, there 9 was a significant correlation between the neutralizing antibody titers and the numbers of NP- In this study, we characterized SARS-CoV-2-specific humoral and cellular immunity in 2 recovered patients. Both were detected in newly discharged patients. In addition, the 3 neutralizing antibody titers significantly correlated with the numbers of NP-specific T cells.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 330,
                    "end": 339,
                    "text": "Figure 3C",
                    "ref_id": null
                },
                {
                    "start": 1190,
                    "end": 1199,
                    "text": "Figure 3C",
                    "ref_id": null
                }
            ],
            "section": "21"
        },
        {
            "text": "These findings suggest both B and T cells participate in immune-mediated protection to viral 5 infection. Our work has thus provided a basis for further analysis of protective immunity to 6 SARS-CoV-2, and understanding the pathogenesis of COVID-19, especially in the severe 7 cases. It has also implications in designing an effective vaccine to protect and treat SARS-",
            "cite_spans": [],
            "ref_spans": [],
            "section": "4"
        },
        {
            "text": "In our study, production of S-RBD-specific antibodies were readily detected in recovered 10 patients. Moreover, we observed virus-neutralization activities in these recovered patients.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "4"
        },
        {
            "text": "Not surprisingly, a significant correlation between neutralizing antibody titers and AUC of 12 anti-S-RBD IgG, but not anti-NP IgG, was observed. Anti-S-RBD IgG might be useful in ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "11"
        },
        {
            "text": "Nonetheless, in our study and the one mentioned above, most patients developed 27 measurable neutralization antibodies after infection, suggesting that the viral infection does 1 not curtail adaptive immunity. However, unlike the above-mentioned study, we did not find 2 any correlation between neutralizing antibody titers and patient's age, which could be due to 3 our small sample size. Our results thus need further confirmation in a large cohort of COVID-4 19 patients. In addition, our analysis could not differentiate CD4 + and CD8 + T cell responses, 5 due to the limitation in the amounts of PBMCs obtained and availability of instrumentation. The plasmid (pET28-N-6XHis) generated in this study will be made available on request 7 from the Lead Contact without restriction.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "26"
        },
        {
            "text": "The study did not generate any unique dataset or code. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "9"
        },
        {
            "text": "Committee at Tsinghua University. Informed consent was obtained from all subjects for 19 being included in the study. All patient data were anonymized before study inclusion. See 20 Table 1 for full patient information, including age, sex, and health status.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 182,
                    "end": 189,
                    "text": "Table 1",
                    "ref_id": "TABREF0"
                }
            ],
            "section": "18"
        },
        {
            "text": "Cell Lines 23 HuH-7 cells originally taken from a liver tumor in a Japanese male were cultured in DMEM 1 supplemented with 10% FBS. Cells were grown at 37 \u00b0C in a 5% CO2 setting. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "22"
        },
        {
            "text": "The OD value at 450 nm was calculated.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "15"
        },
        {
            "text": "Neutralizing antibody assay",
            "cite_spans": [],
            "ref_spans": [],
            "section": "17"
        },
        {
            "text": "Pseudovirus expressing the SARS-CoV-2 S protein was produced as described previously 19 (Deng et al., 1997) . pNL43Luci and GP-pCAGGS were co-transfected into 293T cells. 48 ",
            "cite_spans": [
                {
                    "start": 88,
                    "end": 107,
                    "text": "(Deng et al., 1997)",
                    "ref_id": null
                }
            ],
            "ref_spans": [],
            "section": "18"
        },
        {
            "text": "Highlights:",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Highlights and eTOC Blurb"
        },
        {
            "text": "1. SARS-CoV-2-specific antibodies are detected in COVID-19 convalescent subjects.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Highlights and eTOC Blurb"
        },
        {
            "text": "2. Most COVID-19 convalescent individuals have detectable neutralizing antibodies.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Highlights and eTOC Blurb"
        },
        {
            "text": "3. Cellular immune responses to SARS-CoV-2 are found in COVID-19 convalescent Human convalescence sera ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Highlights and eTOC Blurb"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Notes: pt, patient; F, female; M, male; P, positive; N, negative; BT, before treatment; NA",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF1": {
            "text": "Woo et al., 2004), but exhibited defective expression of type I and II interferon (IFN), 16 indicative of poor protective immune responses (Cameron et al., 2008; Thiel and Weber, 17 2008; Vijay and Perlman, 2016). However, to date, there were few studies in characterizing 18 the immune responses (Wolfel et al., 2020; Zhou et al., 2020), especially adaptive immune 19 responses to SARS-CoV-2 infection. Zhou et al. showed that COVID-19 patients exhibited 20 nucleocapsid protein (NP)-specific antibody response, and in one patient, IgM peaked at day 21 9 after disease onset and then switched to IgG by week 2 (Zhou et al., 2020). They also 22 reported that sera from several patients could inhibit SARS-CoV-2 entry in target cells, 23 indicating involvement of humoral immunity. Krammer and colleagues detected anti-S 24 antibodies in three COVID-19 patients as early as 3 days post symptom onset (doi: 25 https://doi.org/10.1101/2020.03.17.20037713). A case report recently published showed the 26 kinetics of T cell subpopulations (T FH , CD4 and CD8) and SARS-CoV-2-specific antibody 27 responses in one COVID-19 patient",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Detection of SARS-CoV-2-specific antibodies in COVID-19 convalescent subjects10To understand immune responses to COVID-19, we assessed 14 patients who recently 11 recovered from the infection. Their clinical and pathological characteristics were shown in 12",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "IgG, but not anti-NP IgG (Figure 2D), suggesting anti-S-RBD IgG might be predictive of 11 serum neutralization capabilities in COVID-19 patients. These findings suggest that most 12 patients post discharge have serum neutralizing SARS-CoV-2 infection. 13 14 Cellular immune responses to SARS-CoV-2 in COVID-19 convalescent subjects",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "10 specific T cells (Figure 3D), indicating that the development of neutralizing antibodies may 11 be correlated with the activation of anti-viral T cells. Thus, effective clearance of virus may 12 need collaborative humoral and cellular immune responses.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "13 analyzing serum neutralization capabilities in COVID-19 patients. Our data are consistent 14 with the work from other investigators (Zhou et al., 2020), in keeping with the role of humoral 15 immunity in blockade of receptor binding during viral entry in host cells. Interestingly, S-16 RBD-specific T cell production of IFN-\u03b3 was also noted, suggesting that S-RBD also induced 17 broader T cell immune responses. S-RBD thus is a promising target for SARS-CoV-2 18 vaccines. 19 Similar to a recent preprint (doi: https://doi.org/10.1101/2020.03.30.20047365) 20 published on line after ours, the titers of neutralizing antibodies were variable in recovered 21 patients, ranging from below detection (<30) to 1936. Patient#9 did not exhibit significant 22 serum virus-neutralizing activities. This patient, though with anti-NP and S-RBD IgM, did not 23 have significant IgG or IgG1 production. Interestingly, this patient had detectable virus-24 specific T cell function. The basis for the neutralization deficiency in this patient and whether 25 the patient can generate neutralizing antibody thereafter needs further investigation.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "Drs. Rong Mu and Zhinan Ying for sharing secondary detection antibodies. We 23 also thank Weijin Huang and Jianhui Nie from the Procuratorate for sharing the plasmids for 24 pseudovirus package. This work was supported in part by grants from the National Key 25 Research and Development Program of China (2016YFC0906200 to CD, 2016YFC130390 26 to LN , and 2020YFA0707800 to XW), Natural Science Foundation of China (31991173, 27 31821003 and 31991170 to CD), Beijing Municipal Science and Technology N. and C.D designed the research and analyzed the data. F. Y., Y.D., P.L., H.G. and F. C.5collected clinical specimens; M.C did most of the experiments at a P3 laboratory. Y.F., H.Z., 6 P. W., J.G., M.G., X.L., L.S., T. C., P.W., C.Z., R. Z. and X.W. performed some experiments 7 or prepared key reagents; L.N, C.Q. and C.D. analyzed the results; L.N. and C.J.F., Yuan, S.,Kok, K.H., To, K.K., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C.C., Poon, R.W.,  7  et al. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus 8indicating person-to-person transmission: a study of a family cluster. Lancet 395, 514-523. 9Deng, H.K., Unutmaz, D.,KewalRamani, V.N., and Littman, D.R. (1997). Expression cloning of 10 new receptors used by simian and human immunodeficiency viruses. Nature 388, 296-300. 11Di Pierro, F., Bertuccioli, A., and Cavecchia, I. (2020). Possible therapeutic role of a highly 12 standardized mixture of active compounds derived from cultured Lentinula edodes mycelia 13 (AHCC) in patients infected with 2019 novel coronavirus. Minerva Gastroenterol Dietol. 14 Haveri, A., Smura, T., Kuivanen, S., Osterlund, P., Hepojoki, J., Ikonen, N., Pitkapaasi, M., 15Blomqvist, S., Ronkko, E.,Kantele, A., et al. (2020). Serological and molecular findings during 16 SARS-CoV-2 infection: the first case study in Finland, January to February 2020. 17Eurosurveillance 25,16-21.  18   Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al.19 (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. 20 Lancet 395, 497-506. 21 Ko, J.H., Muller, M.A., Seok, H., Park, G.E., Lee, J.Y., Cho, S.Y., Ha, Y.E., Baek, J.Y., Kim, S.H., 22 Kang, J.M., et al. (2017). Serologic responses of 42 MERS-coronavirus-infected patients 23 according to the disease severity. Diagn Microbiol Infect Dis 89, 106-111. 24 Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., and 25 Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the 26 ACE2 receptor. Nature. 27 Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. 28 (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications 29 for virus origins and receptor binding. Lancet 395, 565-574. 30 Mahallawi, W.H., Khabour, O.F., Zhang, Q., Makhdoum, H.M., and Suliman, B.A. (2018). 31 MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine 32 profile. Cytokine 104, 8-13. 33 Nicholls, J.M., Poon, L.L., Lee, K.C., Ng, W.F., Lai, S.T., Leung, C.Y., Chu, C.M., Hui, P.K., Mak, 34 K.L., Lim, W., et al. (2003). Lung pathology of fatal severe acute respiratory syndrome. 35 Lancet 361, 1773-1778. 36 Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. 37 (2020). Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. 38 Emerg Microbes Infect 9, 680-686. 39 Phelan, A.L., Katz, R., and Gostin, L.O. (2020). The Novel Coronavirus Originating in Wuhan, 40 China: Challenges for Global Health Governance. JAMA. 41 Shi, Y., Wan, Z., Li, L., Li, P., Li, C., Ma, Q., and Cao, C. (2004). Antibody responses against 42 SARS-coronavirus and its nucleocaspid in SARS patients. J Clin Virol 31, 66-68. 43 Thevarajan, I., Nguyen, T.H.O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C.E., Jia, X.X., 44 Nicholson, S., Catton, M., Cowie, B., et al. (2020). Breadth of concomitant immune 45 responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 46 Thiel, V., and Weber, F. (2008). Interferon and cytokine responses to SARS-coronavirus 1 infection. Cytokine Growth Factor Rev 19, 121-132. 2 Vijay, R., and Perlman, S. (2016). Middle East respiratory syndrome and severe acute 3 respiratory syndrome. Curr Opin Virol 16, 70-76. 4Wang, C., Horby, P.W., Hayden, F.G., and Gao, G.F. (2020). A novel coronavirus outbreak of 5 global health concern. Lancet 395,470-473.  6   Wang, W., Wang, H., Deng, Y., Song, T., Lan, J., Wu, G.,Ke, C., and Tan, W. (2016). 7Characterization of anti-MERS-CoV antibodies against various recombinant structural 8antigens of MERS-CoV in an imported case in China. Emerg Microbes Infect 5, e113. 9Wolfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Muller, M.A., Niemeyer, 10 D., Jones, T.C., Vollmar, P.,Rothe, C., et al. (2020).Virological assessment of hospitalized 11 patients with COVID-2019. Nature. 12 Woo, P.C., Lau, S.K., Wong, B.H., Tsoi, H.W., Fung, A.M., Chan, K.H., Tam, V.K., Peiris, J.S., 13 and Yuen, K.Y. (2004). Detection of specific antibodies to severe acute respiratory syndrome 14 (SARS) coronavirus nucleocapsid protein for serodiagnosis of SARS coronavirus pneumonia. J 15 Clin Microbiol 42, 2306-2309. 16 Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W., Tian, J.H., Pei, 17 Y.Y., et al. (2020). A new coronavirus associated with human respiratory disease in China. 18 Nature. 19Xie, S., Huang, J., Qiao, Q., Zang, W., Hong, S., Tan, H., Dong, C.,Yang, Z., and Ni, L. (2018). 20Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma 21 tumors. Cancer Immunol Immunother 67,1685-1694.  22   Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, 23 C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat 24 origin. Nature. 25Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al.26(2020",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "SARS-CoV-2 NP-and S-RBD-specific antibodies in COVID-19 convalescent 10 individuals. 11 (A) Titration of individual serum samples. (B) Serological responses of 14 COVID-19 12 patients to recombinant NP (top) and S-RBD (bottom). Dilution of 1:50 was used for IgM and 13 1:450 for IgG. (C) Data from the same experiments with (A) were presented as area under 14 curve (AUC). (D) IgG isotypes of 14 COVID-19 patients to recombinant NP and S-RBD. NP, 15 nucleocapsid protein. S-RBD, receptor binding domain of spike protein. The experiment was 16 performed in duplicates. Date are presented as Mean \u00b1 SEM. NP, nucleocapsid protein. S-17 RBD, receptor binding domain of spike protein. HD, healthy donor. Pt, patient. AUC, area 18 under curve. HD#1-3, the sera were collected in 2018. HD#4-6, the sera were from close 19 contacts and collected in 2020. *P<0.05, 0.05<**P<0.001, ***P<0.001. 20 Measurement of neutralizing antibody titers in COVID-19 convalescent 22 individuals. 23 (A) Correlation analysis of neutralizing antibody titers in COV1D-19 patients measured by 24 pseudovirus and live SARS-CoV-2 (n=20). (B) Neutralizing curves of 14 COVID-19 patients 25 measured by pseudovirus-based assay. The experiment with patients was performed in 26 triplicates. The experiment with healthy donors was performed in duplicates. (C) 27 Measurement of neutralizing antibody titers of 14 COVID-19 patients by pseudovirus-based 28 assay. (D) Correlation between NAT50 and AUC of anti-S-RBD (left panel) and anti-NP 29 (right panel) IgG. HD, healthy donor. Pt, patient. AUC, area under curve. NAT50, 30 neutralizing antibody titers. *P<0.05, 0.05<**P<0.001, ***P<0.001.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "T cell responses to recombinant SARS-CoV-2 proteins in COVIDthe frequencies of different immune cell subsets in COVID-19 patients. HD, healthy 4 donors (n=2); D-Pt, discharged patients (n=3); F-Pt, follow-up patients (n=5). (C) IFN-\u03b3 5 ELISpot analysis of COVID-19 patients to recombinant proteins. (D) Correlation analysis of 6 the NAT50 with the numbers of NP-specific T cells (n=14). M protease, main protease. NP, 7 nucleocapsid protein. S-RBD, receptor binding domain of spike protein; NAT50, neutralizing 8 antibody titers.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "samples of COVID-19 patients and healthy donors were obtained from Chui 14 Yang Liu Hospital affiliated to Tsinghua University in Beijing. All procedures followed were in 15 accordance with the ethical standards of the responsible committee on human 16 experimentation (the institutional review board at Tsinghua University) and with the Helsinki 17 Declaration of 1975, as revised in 2000. All studies were approved by the Medical Ethical",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": "His-tagged NP of SARS-CoV-2 was expressed in E. coli by a T7 6 expression system, with 1 mM IPTG induction at 37 \u00baC for 4 h. The recombinant His-tagged 7 S-RBD (amino acids 319-541) was expressed by a Baculovirus system in insect cells(Lan et   8   al., 2020). Purified proteins were identified by SDS-PAGE gels and stained with Coomassie 9 blue. Western blot was performed to confirm their antigenicity by mouse antiwere isolated from anti-coagulant blood using Ficoll-Hypaque gradients (GE14 Healthcare Life Sciences, Philadelphia, PA) as previously described (Xie et al., 2018) under 15 the biosafety level 3 facility in AMMS. To isolate PBMCs, blood diluted with PBS, was gently 16 layered over an equal volume of Ficoll in a Falcon tube and centrifuged for 30-40 minutes at 17 400-500 g without brake. Four layers formed, each containing different cell types. The 18 second layer contained PBMCs. These cells could be gently removed using a Pasteur 19 pipette and added to warm medium or PBS to wash off any remaining platelets. The pelleted 20 cells were then counted and the percentage viability was estimated using Trypan blue 21 staining. Cells were used immediately. IgM/IgG testing, 96-well ELISA plates were coated overnight with recombinant NP and 26 S-RBD (100 ng/well). The sera from COVID-19 patients were incubated for 1 h at 37\u00b0C. An anti-Human IgG-biotin conjugated monoclonal antibody (Cat. Inc. Beijing, China) was used. The OD value at 450 nm was 4 calculated. The area under the curve (AUC) was calculated by Prism GraphpadIgG1/IgG2/IgG3 test, 96 well ELISA plates were coated (80 ng/well) overnight with 8 recombinant NP and S-RBD. Plates were washed and the sera from COVID-19 patients 9 were incubated for 1 h at 37\u00b0C. After washing, an anti-Human IgG1-HRP conjugated 10 monoclonal antibody (Cat. C030248, BaiaoTong Experiment Center, LY), an anti-human 11 IgG2-HRP conjugated monoclonal antibody (Cat. C030245, BaiaoTong Experiment Center, 12 LY) and an anti-human IgG3-HRP conjugated monoclonal antibody (Cat.C030246,13BaiaoTong Experiment Center, LY), all validated by the company for their specificity, were 14 used at a dilution of 1:4000 for 1 h at RT. After washing, TMB substrate solution was added.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF11": {
            "text": "20 hours later, SARS-CoV-2 pseudovirus-containing supernatants were mixed with at least 6 21 serially diluted serum samples from the COVID-19 patients at 37\u00b0C for 1 hour. Then the 22 mixtures were transferred to 96-well plates containing monolayers of Huh-7 cells (Nie et al., 23 2020). 3 hours later, the medium was replaced. After incubation for 48 h, the cells were 24 washed, harvested in lysis buffer and analyzed for luciferase activity by the addition of 25 luciferase substrate. Inhibition rate = [1-(the sample group-the cell control group) / (the virus 26 control group-the cell control group)] x 100%. The neutralizing antibody titer (NAT50) were 27 calculated by performing S-fit analysis via Graphpad Prism 7 software.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF12": {
            "text": "according to the manufacture protocol. Fresh PBMCs were plated in duplicate at 4 150k per well and then incubated 48h with 1uM of recombinant proteins. Spots were then 5 counted using an ELIspot Reader System (AT-Spot2100, atyx). The number of spots was 6 converted into the number of spots per million cells and the mean of duplicate wells plotted. PBMCs were washed with PBS plus 2% FBS (Gibco, Grand Island, NY), and then Fc 10 blocking reagent (Meltenyi Biotec, Inc., Auburn, CA) was added followed by a wash with 11 PBS plus 2% FBS. Cells were then incubated for 30 min on ice with anti-CD45 (H130) BioLegend), anti-CD3 (OKT3) (BioLegend), anti-CD8 (SK1) (BD), anti-CD56 (HCD56) BioLegend), anti-CD38 (HIT2) (BioLegend) and live/dead fixable aqua dye (eF660, 14 eBioscience), washed twice with PBS plus 2% FBS and then stored at 4 \u00b0C until acquired 15 by FACS Verse (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo 16 software (Version 10.0.8, Tree Star Inc., Ashland, Or). 17 18 QUANTIFICATION AND STATISTICAL ANALYSIS19Prism 7 software is used for statistical analysis. Student's t test was performed for two-group 20 analysis. Pearson's correlation coefficients were calculated. P values less than 0.05 were 21 considered to be statistically significant. information includes one figure.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": "Expression and purification of NP and S-RBD proteins. Related to Figure 1, 2 and 28 3.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF14": {
            "text": "Neutralization antibody titers correlate with the numbers of virus-specific T cells. eTOC Blurb: In blood samples from COVID-19 convalescent subjects, Ni et al. have detected SARS-CoV-2-specific humoral and cellular immunity. Most subjects display serum neutralizing activities, which correlate with the numbers of virus-specific T cells.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF16": {
            "text": "Figure 3",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "All the patients initially showed mild symptoms via CT scan and were positive with SARS-CoV-2 nucleic acid testing. Of them, 8 (patients #1-8) were newly discharged,",
            "latex": null,
            "type": "table"
        },
        "TABREF4": {
            "text": "Clinical and pathological characteristics of the COVID-19 patients Pt# Sex Age",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}